<DOC>
	<DOC>NCT02264028</DOC>
	<brief_summary>- To investigate absorption, metabolism and excretion of [14C]-DK-AH 269 CL after oral and intravenous administration in healthy volunteers - To assess the safety and tolerability of DK-AH 269 CL after oral and intravenous administration to healthy volunteers</brief_summary>
	<brief_title>Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>50 to 65 years of age Body Mass Index (BMI) of 19.9 to 29.9 kg/m2 Resting heart rate (HR) (after 5 min. in the supine position) of more than 55 bpm All volunteers will have given their written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation. Any finding at the medical examination (including BP, HR and ECG) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, hematological/oncological, immunological or hormonal disorders Diseases of the central nervous system or psychiatric disorders or neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Intake of drugs with a long halflife (&gt; 24 hours) within ten halflives of the respective drug before enrolment in the study Use of any drugs which might influence the results of the trial within two weeks prior to administration or during the trial Participation in another trial with an investigational drug (≤ two months prior to administration or during the trial) Smoker (&gt; 10 cigarettes or &gt; 3 cigars of &gt; 3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation (≥ 100 mL within 2 months prior to administration or during the trial) Excessive physical activities (within the last week before the study) Any laboratory value outside the reference range and of clinical relevance Inability to comply with dietary regimen of study centre Not necessarily clinically relevant abnormalities, but specific exclusion criteria for the drugs under study or for the study: Subjects at increased risk for development of cardiac arrhythmia (e.g. family history of long QT syndrome or sudden cardiac death) ECG: PR interval &gt; 210 ms HR at rest ≤ 55 beats per minute (bpm) Relevant ophthalmological disease</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>